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Correction
After the publication of this work [1], we found that there
were some mistakes in calculating the percentage of com-
position in Table 1 (1). Clinicopathologic characteristics of
breast cancer subtypes. We are therefore providing the
revised Table 1, with the updated data for rows ‘Mucinous
carcinoma’, ‘Metaplastic carcinoma’ and ‘Others’.I nt h e
sub-content of Table 1, ‘Histological type’,t h et o t a l
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Table 1. Clinicopathologic characteristics of breast cancer subtypes 
         Molecular Subtyping   
  All          Five subtypes    Four subtypes  P value 
between 
five 
subtypes 
*,† 
P value 
between 
four 
subtypes 
**,† 
Variables      IHC-Luminal 
A 
IHC-
Luminal B  IHC-HER2  IHC-BLBC  IHC-
QNBC/5NP 
 
IHC-TNBC 
  N=951    N=486  
51.1% 
N=123 
12.9% 
N=113 
11.9% 
N=139 
14.6% 
N=90 
9.5% 
  N=229 
24.1% 
  No.  (%)   No.  (%)  No.  (%)  No.  (%)  No.  (%)  No.  (%)    No.  (%)     
Age Group (years)                                  <0.001  <0.001 
<50  590  62.0    297  61.1  87  70.7  51  45.1  97  69.8  58  64.4    155  67.7     
>50  361  38.0    189  38.9  36  29.3  62  54.9  42  30.2  32  35.6    74  32.3     
Family history of breast cancer                                  0.006  0.086 
No  916  96.3    470  96.7  121  98.4  111  98.2  126  90.6  88  97.8    214  93.4     
Yes  35  3.7    16  3.3  2  1.6  2  1.8  13  9.4  2  2.2    15  6.6     
Tumor Size                                    0.014  0.006 
< 2 cm  392  41.2    228  46.9  39  31.7  35  31.0  52  37.4  38  42.2    90  39.3     
2-5 cm  493  51.8    231  47.5  75  61.0  64  56.6  76  54.7  47  52.2    123  53.7     
> 5cm  66  6.9    27  5.6  9  7.3  14  12.4  11  7.9  5  5.6    16  7.0     
N Staging                                  0.178  0.014 
N0  498  52.4    246  50.6  52  42.3  63  55.8  89  64.0  48  53.3    137  59.8     
N1  247  25.9    131  27.0  40  32.5  22  19.5  31  22.3  23  25.6    54  23.6     
N2  118  12.4    64  13.2  19  15.4  13  11.5  12  8.6  10  11.1    22  9.6     
N3  88  9.2    45  9.3  12  9.8  15  13.3  7  5.0  9  10.0    16  7.0     
AJCC stage                                  0.014  0.008 
I  254  26.7    148  30.5  19  15.4  22  19.5  38  27.3  27  30.0    65  28.4     
II  467  49.1    221  45.5  69  56.1  57  5.04  78  56.1  42  46.7    120  52.4     
III  230  24.2    117  24.1  35  28.5  34  30.1  23  16.5  21  23.3    44  19.2     
LN involvement                                  0.016  0.020
  
Negative  498  52.4    246  50.6  52  42.3  63  55.8  89  64.0  48  53.3    137  59.8     
Positive  453  47.6    240  49.4  71  57.7  50  44.2  50  36.0  42  46.7    92  40.2     
Nuclear Grade                                  <0.001  <0.001 
Low  92  9.7    67  13.8  5  4.1  3  2.7  9  6.5  8  8.8    17  7.4     
Intermediate  486  51.1    308  63.4  65  52.8  40  35.4  26  18.7  47  52.2    73  31.9     
High  373  39.2    111  22.8  53  43.1  70  61.9  104  74.8  35  38.9    139  60.7     
Histological Grade                                  <0.001  <0.001 
Well  100  10.5    63  13.0  10  8.1  11  9.7  8  5.8  8  8.9    16  7.0     
Moderate  597  62.8    334  68.7  76  61.8  65  57.5  71  51.1  51  56.7    122  53.3     
Poor  254  26.7    89  18.3  37  30.1  37  32.7  60  43.2  31  34.4    91  39.7     
Estrogen Receptor (ER)                                  <0.001  <0.001 
Negative  364  38.3    11  2.3  11  8.9  113  100.0  139  100.0  90  100.0    229  100.0     
Positive  587  61.7    475  97.7  112  91.1  0  0.0  0  0.0  0  0.0    0  0.0     
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composition of ‘Others’ type was slightly changed accord-
ing to breast cancer subtypes. For IHC-Her2 subtype, the
number of ‘Others’ was changed from 4 to 3, and 6 cases
which were previously unidentified were assigned to corre-
sponding subtypes. One case to IHC-BLBC, 2 cases to
IHC-QNBC/5NP and 3 cases to IHC-TNCB. There was
no effect on statistical analysis with the correction.
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